In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $64.55 up 0.25% from its previous closing price of $64.39. In other words, the price has increased by $+0.16 from its previous closing price. On the day, 2384744 shares were traded. CYTK stock price reached its highest trading level at $66.00 during the session, while it also had its lowest trading level at $62.62.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.12 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 05 ’24 when Malik Fady Ibraham sold 32,604 shares for $67.56 per share. The transaction valued at 2,202,606 led to the insider holds 138,973 shares of the business.
HENDERSON JOHN T sold 5,000 shares of CYTK for $382,400 on Feb 14 ’24. The Director now owns 42,632 shares after completing the transaction at $76.48 per share. On Feb 13 ’24, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 12,500 shares for $76.85 each. As a result, the insider received 960,625 and left with 441,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6.65B and an Enterprise Value of 6.79B. For the stock, the TTM Price-to-Sale (P/S) ratio is 882.95. Its current Enterprise Value per Revenue stands at 901.71 whereas that against EBITDA is -14.87.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 79.89, while the 200-Day Moving Average is calculated to be 45.97.
Shares Statistics:
For the past three months, CYTK has traded an average of 3.83M shares per day and 2.41M over the past ten days. A total of 101.64M shares are outstanding, with a floating share count of 99.34M. Insiders hold about 3.56% of the company’s shares, while institutions hold 109.61% stake in the company. Shares short for CYTK as of Feb 29, 2024 were 14.53M with a Short Ratio of 3.79, compared to 13.58M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.11% and a Short% of Float of 23.05%.
Earnings Estimates
There are 14 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$0.89 and a low estimate of -$1.36, while EPS last year was -$1.38. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.82 and low estimates of -$1.38.
Analysts are recommending an EPS of between -$3.43 and -$5.5 for the fiscal current year, implying an average EPS of -$4.45. EPS for the following year is -$3.36, with 13 analysts recommending between -$1.53 and -$5.23.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $146.24M in the next fiscal year. The high estimate is $394.65M and the low estimate is $5M. The average revenue growth estimate for next year is up 2,125.90% from the average revenue estimate for this year.
